# Evaluate Bioequivalence of Micafungin (50mg/Vial)

> **NCT05496725** · PHASE4 · COMPLETED · sponsor: **Yung Shin Pharm. Ind. Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Invasive Candidiasis

## Interventions

- **DRUG:** Micafungin

## Key facts

- **NCT ID:** NCT05496725
- **Lead sponsor:** Yung Shin Pharm. Ind. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-06
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-07-28
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496725, "Evaluate Bioequivalence of Micafungin (50mg/Vial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05496725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*